药物洗脱球囊治疗冠状动脉粥样硬化性心脏病效果分析

Efficacy analysis of drug-eluting balloon in treating coronary atherosclerotic heart disease

目的观察药物洗脱球囊治疗冠状动脉粥样硬化性心脏病（冠心病）的有效性和安全性。方法选择2015年1—8月于首都医科大学附属北京安贞医院心内科住院行药物洗脱球囊治疗的64例冠心病患者作为观察组，每例患者匹配1例同期、同一病变类型、年龄相近的行药物洗脱支架治疗的冠心病患者组成对照组。于术后3、9、12个月时进行电话或门诊随访，统计患者心绞痛发作及死亡、急性心肌梗死、靶病变再次血运重建等主要不良心脏事件（MACE）发生情况。结果随访至术后3、9、12个月时，观察组和对照组患者心绞痛和MACE发生率差异均无统计学意义[心绞痛：14．1％（9／64）比21．9％（14／64），P=0．250；15．6％（10／64）比23．4％（15／64），P=0．265；15．6％（10／64）比26．6％（17／64），P=0．129；MACE：4．7％（3／64）比3．1％（2／64），P=0．648；7．8％（5／64）比9．4％（6／64），P=0．752；10．9％（7／64）比12．5％（8／64），P：0．783]。观察组有3例患者在术后3个月内停用双联抗血小板药物，仅服用1种抗血小板药物；有1例患者在随访至术后3个月时完全停用抗血小板药物；至术后12个月时，该4例患者均未出现MACE。结论药物洗脱球囊治疗冠心病的临床效果和安全性满意，可作为目前经皮冠状动脉介入术的重要补充。

Objective To observe efficacy and safety of drug-eluting balloon in the treatment of coronary atherosclerotic heart disease（CHD）. Methods Sixty-four patients with CHD who had drug-eluting balloon therapy from January 2015 to August 2015 in Beijing Anzhen Hospital, Capital Medical University were enrolled as observation group; each patient was matched with 1 case of CHD with same lesion type and similar age who had drug-eluting stents therapy as control group. All patients were followed up for 12 months after operation. Incidence of angina pectoris attack and major adverse cardiac events （MACE） （death, acute myocardial infarction, target lesion revascularization） were recorded at 3, 9, 12 months after operation. Results Incidences of angina pectoris and MACE had no significant differences between observation and control group at 3, 9, 12 months after operation [ angina pectoris ： 14. 1% （9/64） vs 21.9% （ 14/64）, P = 0. 250 ; 15.6% （10/64） vs 23.4% （ 15/64）, P = 0.265; 15.6%（10/64） vs 26.6% （17/64）, P=0. 129; MACE： 4.7%（3/64） vs 3.1% （2/64）, P =0.648; 7.8% （5/64） vs 9. 4% （6/64）, P =0. 752; 10. 9% （7/64） vs 12. 5% （8/64）, P =0. 7831- At 3 months after operation, 3 patients in observation group discontinued dual-antiplatelet agents and took single antiplatelet agent; 1 patient completely stopped antiplatelet agents; those 4 patients had no MACE until 12 months after operation. Conclusion Clinical efficacy and safety of drug-eluting balloon in the treatment of CHD are optimistic.